Pharma Times -- t looks like patients with advanced cancer of the urothelial tract will not be getting access to Pierre-Fabre’s Javlor on the National Health Service, after the drug was deemed too expensive by NICE.
Pharma Times -- t looks like patients with advanced cancer of the urothelial tract will not be getting access to Pierre-Fabre’s Javlor on the National Health Service, after the drug was deemed too expensive by NICE.
